| SC 13G | 2019-01-22 | JOHNSON & JOHNSON | Provention Bio, Inc. | 2,400,000 | 6.4% | EDGAR |
| SC 13G | 2019-01-22 | JOHNSON & JOHNSON | PhaseBio Pharmaceuticals Inc | 1,616,863 | 6.6% | EDGAR |
| SC 13G | 2018-02-14 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.8% | EDGAR |
| SC 13G/A | 2018-02-09 | VANGUARD GROUP INC | JOHNSON & JOHNSON | 204,466,526 | 7.6% | EDGAR |
| SC 13G/A | 2018-02-08 | BlackRock Inc. | JOHNSON & JOHNSON | 167,535,883 | 6.2% | EDGAR |
| SC 13G/A | 2018-01-22 | JOHNSON & JOHNSON | CATALYST BIOSCIENCES, INC. | 91,826 | 1.6% | EDGAR |
| SC 13G/A | 2018-01-22 | JOHNSON & JOHNSON | Tracon Pharmaceuticals, Inc. | 840,022 | 4.8% | EDGAR |
| SC 13G/A | 2017-11-22 | JOHNSON & JOHNSON | ACHILLION PHARMACEUTICALS INC | - | - | EDGAR |
| SC 13G/A | 2017-09-14 | JOHNSON & JOHNSON | Minerva Neurosciences, Inc. | - | - | EDGAR |
| SC 13G/A | 2017-02-10 | VANGUARD GROUP INC | JOHNSON & JOHNSON | 191,188,744 | 7.0% | EDGAR |
| SC 13G | 2017-02-07 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.6% | EDGAR |
| SC 13G/A | 2017-01-25 | BlackRock Inc. | JOHNSON & JOHNSON | 170,679,367 | 6.3% | EDGAR |
| SC 13G/A | 2017-01-18 | JOHNSON & JOHNSON | NEVRO CORP | 1,400,824 | 4.9% | EDGAR |
| SC 13G | 2017-01-18 | JOHNSON & JOHNSON | Merus N.V. | 1,195,943 | 7.4% | EDGAR |
| SC 13G | 2016-10-31 | JOHNSON & JOHNSON | Tracon Pharmaceuticals, Inc. | 840,022 | 6.4% | EDGAR |
| SC 13G | 2016-08-19 | JOHNSON & JOHNSON | Protagonist Therapeutics, Inc | 2,449,183 | 15.0% | EDGAR |
| SC 13G | 2016-02-16 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.4% | EDGAR |
| SC 13G/A | 2016-02-12 | JOHNSON & JOHNSON | GENOCEA BIOSCIENCES, INC. | 1,330,305 | 4.7% | EDGAR |
| SC 13G/A | 2016-02-12 | JOHNSON & JOHNSON | NEVRO CORP | 2,066,740 | 7.4% | EDGAR |
| SC 13G/A | 2016-02-12 | JOHNSON & JOHNSON | AQUINOX PHARMACEUTICALS, INC | 0 | 0.0% | EDGAR |